Clinical Experience and Major Learning Points Following the Implementation of the sFlt-1/PlGF Ratio in the Management of Suspected Preeclampsia in a South Australian Tertiary Hospital
( Aust N Z J Obstet Gynaecol . 2025;65(6):860–866. doi: 10.1111/ajo.70046) Understanding of the pathophysiology of preeclampsia (PEC) has progressed rapidly in recent years, particularly with the discovery of an imbalance between placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1). The sFlt-1/PlGF ratio has been shown to be a clinically useful negative predictive marker for the development of PEC; patients with a ratio less than 38 had a negative predictive value of 99.2% for severe PEC. This test was introduced in a local health care network in October of 2021. To date, there is no literature surrounding the implementation of this marker in Australia. This study was a retrospective audit designed to assess how the ratio was ordered and used, provide feedback to clinicians, and provide suggestions for optimization.
Authors
- Lu Amy
- G Dekker
- A Lane
- A Parange
Publication Details
- Journal
- Obstetric Anesthesia Digest
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1097/01.aoa.0001288928.29265.43
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00